Business context and reporting period
Important identity note: The supplied filing is ESGEN Acquisition Corporation’s Form 10-Q, not a filing by Zeo Energy Corp. It covers the quarter ended September 30, 2023, and was signed November 14, 2023. ESGEN was a shell company seeking a business combination and had no operating revenue or operating business during the period. Its proposed target was Sunergy Renewables, LLC.
Financial results and liquidity
| Metric | Q3 2023 / September 30, 2023 | Comparable period |
|---|---|---|
| Revenue | No operating revenue | No operating revenue |
| Net income (loss) | $631,724 for the quarter | $4,262,070 income in Q3 2022 |
| Operating costs | $829,000 for the quarter | $329,275 in Q3 2022 |
| Cash and current assets | $267,058 cash; $271,319 total current assets | $614,767 cash at December 31, 2022 |
| Trust Account | $32,393,380 | $285,506,568 at December 31, 2022 |
| Current liabilities | $7,015,026 | $2,182,531 at December 31, 2022 |
| Warrant liabilities | $1,002,240 | $796,224 at December 31, 2022 |
Quarterly income reflected a $1,046,784 gain from the change in fair value of warrant liabilities and $413,940 in Trust Account dividends, partly offset by operating costs. For the nine months ended September 30, 2023, ESGEN reported a $2,225,459 net loss, versus $11,637,242 net income in the prior-year period; operating costs rose to $4,164,293 from $1,604,008. The prior-year profit was substantially driven by warrant fair-value gains.
For the nine months, operating cash flow was positive $1,176,412, investing cash flow was positive $253,113,188, and financing cash flow was negative $254,637,309, principally reflecting redemptions and Trust Account movements. Cash declined by $347,709 to $267,058. No meaningful operating margins can be assessed because the company had no revenue. The filing reports no market or interest-rate risk considered material at September 30.
Material changes and unusual items
- In January 2023, holders redeemed 24,703,445 public shares for approximately $255.9 million, materially reducing the Trust Account.
- In April, underwriters waived the $9.66 million deferred underwriting fee. ESGEN recorded $425,040 as other income and $9,234,960 as a reduction to accumulated deficit.
- Accounts payable and accrued expenses increased to $5,296,038, primarily legal accruals, from $1,866,992 at year-end 2022.
- Related-party promissory note borrowings were $1,409,795 at September 30; the filing also reports $309,193 due to related parties. Management cites total related-party obligations of $1,718,988.
Outlook, risks and contingencies
ESGEN had agreed to combine with Sunergy under an April 2023 business combination agreement. The filing expected closing in Q1 2024, subject to shareholder approval, regulatory and listing conditions, an effective registration statement, and other customary conditions. The agreement required at least $20 million in aggregate transaction proceeds and included a $10 million Sponsor PIPE commitment, contingent on closing, with efforts to obtain additional financing. Completion was not assured.
At the October 20, 2023 shareholder meeting, after quarter-end, shareholders extended the deadline to January 22, 2024, with possible additional one-month extensions, subject to Sponsor deposits. The meeting also approved a change allowing Class B shares to convert earlier; the Sponsor converted 5,619,077 shares. A further 1,488,000 public shares were redeemed for approximately $16.7 million, and the Sponsor deposited $73,949 into the Trust Account. The filing states 7,027,632 Class A shares remained outstanding after those actions. An amended Sponsor note of up to $2.5 million was issued October 17; amounts are non-interest-bearing and repayable only from funds outside the Trust Account.
Management stated that the $267,058 of cash outside the Trust Account was insufficient to fund operations for at least 12 months absent a business combination. The potential mandatory liquidation if a combination or extension is not completed, together with funding constraints, raised substantial doubt about going concern. On October 16, ESGEN directed that Trust Account investments be liquidated and funds held in demand deposits to address investment-company-status concerns; this may reduce future Trust Account earnings.
Disclosure controls were deemed ineffective because a previously identified material weakness persisted, including inadequate accounting expertise and control deficiencies involving earnings per share and cash-flow classification. Management described remediation efforts but gave no assurance they would succeed. The company also identified risks relating to business-combination execution, redemptions, financing, potential investment-company regulation, and liquidation; warrants could expire worthless if ESGEN liquidates. No legal proceedings were reported.
Most important facts for investors to verify
- Confirm the issuer: this filing is for ESGEN Acquisition Corporation, not Zeo Energy Corp.
- Check the current status and final terms of the ESGEN–Sunergy transaction, including shareholder and regulatory approvals, financing, proceeds threshold, and any later amendments.
- Verify the operative deadline and any extensions. The filing describes January 22, 2024 and possible extensions, while portions of its risk disclosure refer to a July 22, 2024 outside date.
- Review post-quarter redemptions, remaining public shares, Trust Account balance, and cash available outside the Trust Account.
- Assess Sponsor funding capacity and related-party balances, given the substantial-doubt going-concern disclosure.
- Track remediation of the material weakness and whether control effectiveness improves.